The federal government has filed a rebuttal to the Pharmaceutical Research & Manufacturers of America’s argument that drug companies face liability for engaging in truthful speech about “off-label” uses of drugs.
According to the organization’s amicus brief in United States v. Millenium Pharmaceuticals Inc., the government and its relator allege that the manufacturer submitted false claims to the government for Integrilin by circulating articles reprinted from Cardiology, the American Heart Journal and the American Journal of Cardiology about unapproved uses. The federal government, more than 20 states and federal territories and relator Frank Solis have brought claims under the False Claims Act.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
